We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Tools Developed for Early Meningitis Diagnosis

By LabMedica International staff writers
Posted on 28 Sep 2010
A predictive model based on two blood tests and a clinical sign will allow physicians assess whether or not a suspected case of meningitis is bacterial or viral in origin. More...


Bacterial meningitis is a serious infection of the fluid in the spinal cord and the fluid that surrounds the brain commonly caused by three types of bacteria: Haemophilus influenzae type b, Neisseria meningitidis, and Streptococcus pneumoniae bacteria. The diagnosis is usually made by growing the bacteria in culture from cerebral spinal fluid obtained from a lumbar puncture.

In a recent report from the UK Health Protection Agency's (HPA; London, UK) annual conference, analysis of data collected on 720 patients from all probable cases of bacterial and viral meningitis was presented. The patients had been admitted to participating hospitals in the South West, West Midlands and London regions of England. The date was collected from July 1, 2008 and June 30, 2009.

After examining the clinical symptoms, biochemistry and microbiology of 385 confirmed cases of meningitis over a 12 month period, the team identified three factors based on routine clinical assessment and early available laboratory test results that help differentiate between bacterial and viral meningitis. The results showed that the peripheral polymorphonuclear leukocyte (PMN) count, C-reactive protein level in the blood and rash are strongly associated with bacterial meningitis. Leukocyte PMN counts above 16 × 109/L, and a C-reactive protein level of more than 100 mg/L associated with a hemorrhagic rash, were most likely to be found in confirmed cases of bacterial meningitis. The normal PMN count varies with age, but the range is usually between 2.5 × 109/L to 7.5 × 109/L and a normal C-reactive protein is less than 10mg/L.

Oluwatoyin O. Ejidokun M.B. B.S., M.Sc., Ph.D.,, who led the study team, said, "While further testing needs to take place to test the accuracy of the model, this simple model offers the prospect of a rapid predictive tool to help clinical and public health management of suspected bacterial meningitis cases." Swift diagnosis of bacterial meningitis is crucial to protecting public health as it means potentially lifesaving interventions can be put in places, such as prescribing antibiotics to the patient and people they have been in contact with.
Related Links:
UK Health Protection Agency




Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Aspiration System
VACUSAFE
Automated Clinical Chemistry Analyzer
Envoy 500+
New
Gold Member
Platelet Function Analyzer
PL-12
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: Signatera uses ctDNA analysis to identify residual tumor-derived genetic material after definitive treatment (image credit: Adobe Stock)

Blood-Based MRD Test Predicts Recurrence Risk After Lung Cancer Surgery

Assessing recurrence risk after surgery for early-stage non-small cell lung cancer remains challenging, complicating adjuvant therapy and surveillance decisions. Blood-based molecular residual disease... Read more

Immunology

view channel
Image: Although many people harbor latent Epstein-Barr virus (EBV), growing evidence has linked the virus to MS pathobiology (Image Credit: Adobe Stock)

Blood EBV Activity Biomarkers May Predict Multiple Sclerosis Relapse Months Ahead

Predicting relapse in multiple sclerosis (MS) remains difficult, limiting opportunities for timely intervention and monitoring. Although many people harbor latent Epstein-Barr virus (EBV), growing evidence... Read more

Microbiology

view channel
Image: Type 1 diabetes affects more than 9 million people worldwide and can begin years before symptoms appear, making early identification of at-risk children difficult (Image Credit: iStock)

Early-Life Gut Microbiome Changes May Help Assess Type 1 Diabetes Risk

Type 1 diabetes (T1D) affects more than 9 million people worldwide, including 1.8 million children and adolescents, and often begins years before symptoms appear. Early identification of children who are... Read more

Pathology

view channel
Image: A new study demonstrates that vascular features in colorectal tumors could serve as prognostic biomarkers of disease outcome. (Image Credit: iStock)

Tumor Blood Vessel Features May Help Predict Colorectal Cancer Survival

Colorectal cancer outcomes vary widely, and tumor biology remains a key determinant of prognosis. Because neoplasms depend on a vascular supply, differences in intratumoral vessels may influence survival.... Read more

Technology

view channel
Image: ADLM recommends that emerging AI tools follow the same professional oversight, quality, validation, and monitoring standards as traditional clinical testing within CLIA’s existing framework (Image Credit: Adobe Stock)

ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine

Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read more

Industry

view channel
Image: Central to the collaboration is the Enhanced Liver Fibrosis (ELF) test, a noninvasive blood test authorized in the U.S. to assess disease progression risk in patients with advanced fibrosis due to MASH and support patient management decisions. (Photo courtesy of Siemens Healthineers)

Siemens Healthineers and Novo Collaborate to Expand Access to Noninvasive Liver Testing

Metabolic dysfunction‑associated steatotic liver disease (MASLD) and its progressive form, metabolic dysfunction‑associated steatohepatitis (MASH), affect millions and are linked to obesity, type 2 diabetes,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.